Barricade Therapeutics
Barricade Therapeutics42
About
What does Barricade Therapeutics do?
Barricade Therapeutics is advancing a first-in-class oral therapy, BT-1501, to treat colorectal cancer. The company is addressing the unmet need for improved therapeutic strategies, particularly as colorectal cancer incidence rises among younger adults and resistance to existing treatments is common.
What is Barricade Therapeutics's revenue?
StartupHub estimates Barricade Therapeutics's annual revenue at $5.7M (range $3.2M to $17.2M, 63% confidence), based on comparable companies in the sector.
Where is Barricade Therapeutics headquartered?
Barricade Therapeutics is headquartered in San Diego, United States.
When was Barricade Therapeutics founded?
Barricade Therapeutics was founded in 2017.
What industry does Barricade Therapeutics operate in?
Barricade Therapeutics operates in Biotech, HealthTech, Drug Discovery, Oncology.
How many employees does Barricade Therapeutics have?
Barricade Therapeutics has approximately 25 people on record.
No comments yet. Be the first to share your take.